Search results for "uva"

showing 10 items of 2916 documents

Laparoscopic Splenectomy for Secondary Cytoreduction in Ovarian Cancer Patients With Localized Spleen Recurrence: Feasibility and Technique

2016

Abstract Study Objective To investigate the feasibility of laparoscopic splenectomy in patients with recurrent ovarian cancer with isolated spleen metastasis. Design (Canadian Task Force classification III). Setting Tertiary referral centre in Rome, Italy. Patients Eight women with an isolated platinum-sensitive splenic relapse of ovarian cancer. Intervention Between February 2013 and May 2015, 8 women with an isolated platinum-sensitive splenic relapse of ovarian cancer were submitted to laparoscopic splenectomy. Measurements and Main Results All patients underwent laparoscopic splenectomy without conversion to an open approach. The median estimated intraoperative blood loss was 100 mL (ra…

Adultmedicine.medical_specialtyIntraoperative ComplicationSettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatmentOperative TimeSplenectomySpleenLaparoscopic splenectomy03 medical and health sciences0302 clinical medicineObstetrics and gynaecologymedicineHumansLaparoscopyAgedOvarian Neoplasms030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industrySplenic NeoplasmsObstetrics and GynecologyCytoreduction Surgical ProceduresLength of StayMiddle Agedmedicine.diseaseSurgeryTreatment Outcomemedicine.anatomical_structureItalyChemotherapy AdjuvantRecurrent Ovarian Cancer030220 oncology & carcinogenesisSplenectomyFeasibility StudiesFemaleLaparoscopyRecurrent ovarian cancerNeoplasm Recurrence LocalbusinessOvarian cancerFollow-Up StudiesJournal of Minimally Invasive Gynecology
researchProduct

Robotic Radical Hysterectomy After Concomitant Chemoradiation in Locally Advanced Cervical Cancer: A Prospective Phase II Study

2016

Study Objective To assess the feasibility of total robotic radical surgery (TRRS) in patients with locally advanced cervical cancer (LACC) who receive chemoradiation therapy (CT/RT). Design A prospective (preplanned) study of a nonrandomized controlled trial (Canadian Task Force classification level 2). Setting Catholic University of the Sacred Hearth, Rome, Italy. Patients Between September 2013 and January 2016, a total of 40 patients with LACC (Fédération Internationale de Gynécologie et d'Obstétrique stage IB2–III) were enrolled in the study. Interventions Robotic radical hysterectomy (RRH) plus pelvic and/or aortic lymphadenectomy was attempted within 6 weeks after CT/RT. The feasibili…

Adultmedicine.medical_specialtyLocally advancedPhases of clinical researchUterine Cervical NeoplasmsChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomyHysterectomy03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRobotic Surgical ProceduresRobotic radical hysterectomymedicineHumansIn patientRadical surgeryRadical HysterectomyChemoradiation; Locally advanced cervical cancer; Robotic radical hysterectomy; Obstetrics and GynecologyAgedCervical cancerLocally advanced cervical cancer030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyChemoradiotherapy AdjuvantMiddle Agedmedicine.diseaseCombined Modality TherapySurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAChemoradiation030220 oncology & carcinogenesisConcomitantCarcinoma Squamous CellDisease ProgressionFeasibility StudiesLymph Node ExcisionFemaleLaparoscopybusiness
researchProduct

Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis.

1993

Primary biliary cirrhosis is characterised by the presence of antimitochondrial antibodies which are directed against components of mitochondrial dehydrogenase complexes. The specificity of antimitochondrial antibodies for primary biliary cirrhosis as detected by immunoblotting was investigated. Commercially available preparations of pyruvate and oxo-glutarate dehydrogenases and beef-heart mitochondria were used as source of antigens. Sera from 47 primary biliary cirrhosis patients (46 of whom were antimitochondrial antibody positive by immunofluorescence), 16 non-primary biliary cirrhosis patients (antimitochondrial antibody positive by immunofluorescence), 23 liver-kidney microsomal antib…

Adultmedicine.medical_specialtyPathologyBiliary cirrhosisImmunoblottingFluorescent Antibody TechniquePyruvate Dehydrogenase ComplexBiologyImmunofluorescenceGastroenterologyMitochondria HeartPrimary biliary cirrhosisAntigenAntibody SpecificityInternal medicinemedicineAnimalsHumansKetoglutarate Dehydrogenase ComplexAutoantibodiesHepatitismedicine.diagnostic_testLiver Cirrhosis BiliaryGastroenterologyAutoantibodyMiddle AgedPyruvate dehydrogenase complexmedicine.diseaseMitochondriabiology.proteinCattleFemaleAntibodyResearch ArticleGut
researchProduct

Pulmonary artery sarcoma with angiosarcoma phenotype mimicking pleomorphic malignant fibrous histiocytoma: a case report

2012

Abstract Primary sarcomas of the major blood vessels can be classified based on location in relationship to the wall or by histologic type. Angiosarcomas are malignant neoplasms that arise from the endothelial lining of the blood vessels; those arising in the intimal compartment of pulmonary artery are rare. We report a case of pulmonary artery angiosarcoma in a 36-year old female with pulmonary masses. The patient had no other primary malignant neoplasm, thus excluding a metastatic lesion. Gross examination revealed a thickened right pulmonary artery and a necrotic and hemorrhagic tumor, filling and occluding the vascular lumen. The mass extended distally, within the pulmonary vasculature …

Adultmedicine.medical_specialtyPathologyHistologyBiopsyHemangiosarcomaCase ReportHistiocytoma Malignant FibrousPathology and Forensic MedicinePredictive Value of Testsmedicine.arteryVascular NeoplasmBiomarkers TumorAngiosarcomalcsh:PathologyMedicineHumansAngiosarcomaDiagnostic ErrorsPneumonectomyCell ProliferationPulmonary Artery AngiosarcomaLungbusiness.industrySarcomaGeneral Medicinemedicine.diseaseRight pulmonary arteryImmunohistochemistryVascular NeoplasmsPulmonary arteryHemangiosarcomamedicine.anatomical_structurePhenotypeTreatment OutcomeChemotherapy AdjuvantPulmonary arteryFemaleSarcomaRadiologybusinessTomography X-Ray Computedlcsh:RB1-214Diagnostic Pathology
researchProduct

Uterine leiomyoma metastasis as a first sign of breast cancer

1998

Uterine metastases from extragenital cancer are rarely reported in the literature. More frequently, the female genital tract is involved by direct extension from an adjacent pelvic organ. A 37-year-old woman had a myoma of the uterine wall and hypermenorrhea. The mass was laparoscopically enucleated, and frozen section examination was performed because it was macroscopically suspicious for sarcomatoid degeneration. The final diagnosis was metastatic carcinoma in the uterus of probable breast origin.

Adultmedicine.medical_specialtyPathologyUterusAntineoplastic AgentsBreast NeoplasmsMetastatic carcinomaMetastasisFatal OutcomeBreast cancermedicineHumansGynecologyFrozen section procedureUterine leiomyomaLeiomyomabusiness.industryBiopsy NeedleObstetrics and GynecologyCancerMyomamedicine.diseaseImmunohistochemistrymedicine.anatomical_structureChemotherapy AdjuvantLymphatic MetastasisUterine NeoplasmsFemaleLaparoscopyRadiotherapy AdjuvantbusinessThe Journal of the American Association of Gynecologic Laparoscopists
researchProduct

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adultmedicine.medical_specialtyProstate biopsymedicine.medical_treatment030232 urology & nephrologyUrologyAntineoplastic Agents03 medical and health sciencesProstate cancer0302 clinical medicineAdjuvants ImmunologicBiopsyIntravesical instillation Prostate cancer PSAmedicineAdjuvant therapyCombined Modality TherapyHumansNeoplasm InvasivenessAgedAged 80 and overChemotherapyBladder cancermedicine.diagnostic_testbusiness.industryGeneral MedicineImmunotherapyMiddle AgedProstate-Specific Antigenmedicine.diseaseCombined Modality TherapyAdministration IntravesicalUrinary Bladder Neoplasms030220 oncology & carcinogenesisBCG VaccinebusinessUrologia
researchProduct

Is intravesical instillation of hyaluronic acid and chondroitin sulfate useful in preventing recurrent bacterial cystitis? A multicenter case control…

2015

Abstract Objective Urinary tract infections (UTIs) are common in the female population and, over a lifetime, about half of women have at least one episode of UTI requiring antibiotic therapy. The aim of the current study was to compare two different strategies for preventing recurrent bacterial cystitis: intravesical instillation of hyaluronic acid (HA) plus chondroitin sulfate (CS), and antibiotic prophylaxis with sulfamethoxazole plus trimethoprim. Materials and methods This was a retrospective review of two different cohorts of women affected by recurrent bacterial cystitis. Cases (experimental group) were women who received intravesical instillations of a sterile solution of high concen…

Adultmedicine.medical_specialtyRecurrent bacterial cystitismedicine.drug_classUrinary systemCystitiAntibioticsUrinalysislcsh:Gynecology and obstetricsGastroenterologyantibioticsantibiotics; chondroitin sulfate; cystitis; hyaluronic acidchemistry.chemical_compoundAdjuvants ImmunologicRecurrenceInternal medicineObstetrics and GynaecologyHyaluronic acidCystitismedicineHumansChondroitin sulfateAntibiotic prophylaxisHyaluronic Acidlcsh:RG1-991antibiotics chondroitin sulfate cystitis hyaluronic acidchondroitin sulfateRetrospective StudiesDose-Response Relationship Drugbusiness.industrySulfamethoxazoleChondroitin SulfatesAntibioticObstetrics and GynecologySettore MED/40 - Ginecologia E OstetriciaTrimethoprimSurgeryAdministration IntravesicalInstillation DrugchemistryUrinary Tract InfectionsDrug Therapy CombinationFemalebusinessmedicine.drugFollow-Up StudiesTaiwanese journal of obstetricsgynecology
researchProduct

Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.

2018

Abstract Background Cardiac toxicity with a decrease of the left ventricular ejection fraction (LVEF) is the main side effect induced by trastuzumab. This study reports the fluctuation of LVEF over the 12 months of adjuvant trastuzumab in PHARE trial (NCT00381901). Methods LVEF assessment was performed every 3 months while patients received trastuzumab and after completion of treatment over the first 2 years and then every 6 months afterwards. The fluctuations of LVEF over time were described and a logistic regression model was performed investigating associated factors to LVEF perfect recovery at baseline value. Results A total of 1631 patients who received 12 months of trastuzumab from PH…

Adultmedicine.medical_specialtySide effectReceptor ErbB-2medicine.medical_treatmentBreast Neoplasms030204 cardiovascular system & hematologyVentricular Function Left03 medical and health sciences0302 clinical medicineBreast cancerAntineoplastic Agents ImmunologicalTrastuzumabInternal medicinemedicineHumansIn patientcardiovascular diseasesCardiotoxicityEjection fractionbusiness.industryGeneral MedicineMiddle AgedTrastuzumabmedicine.diseaseCardiotoxicityStandard errorChemotherapy AdjuvantEchocardiography030220 oncology & carcinogenesiscardiovascular systemCardiologySurgeryFemalebusinessAdjuvantcirculatory and respiratory physiologymedicine.drugFollow-Up StudiesBreast (Edinburgh, Scotland)
researchProduct

Heavy Resistance Training in Breast Cancer Patients Undergoing Adjuvant Therapy.

2019

BACKGROUND AND PURPOSE Adjuvant breast cancer therapy may reduce maximal muscle strength, muscle mass, and functional performance. Although maximal strength training (MST) has the potential to counteract this debilitating outcome and is shown to be superior to low- and moderate-intensity strength training, it is unknown if it can elicit effective adaptations in patients suffering treatment-induced adverse side effects. METHODS Fifty-five newly diagnosed stage I to III breast cancer patients (49 ± 7 yr) scheduled for adjuvant therapy were randomized to MST or a control group. The MST group performed 4 × 4 repetitions of dynamic leg press at approximately 90% of one-repetition maximum (1RM) t…

Adultmedicine.medical_specialtyStrength trainingmedicine.medical_treatmentUrologyPhysical Therapy Sports Therapy and RehabilitationBreast NeoplasmsWalkingMastectomy SegmentalBody Mass IndexQuadriceps Muscle03 medical and health sciences0302 clinical medicineBreast cancerAdjuvant therapyMedicineHumansOrthopedics and Sports MedicineMuscle StrengthAdverse effectLeg pressbusiness.industryResistance Training030229 sport sciencesMiddle AgedPhysical Functional Performancemedicine.diseaseQuadriceps femoris muscleRadiation therapyLower ExtremityThighChemotherapy AdjuvantFemaleRadiotherapy Adjuvantbusinesshuman activitiesBody mass indexMedicine and science in sports and exercise
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct